Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
T8 (Leitengshu) for Chronic Abnormal Immune Activation in HIV/AIDS
NCT04084444Phase 2Completed
- Sponsor
- Shanghai Pharmaceuticals Holding Co Ltd
- Start
- Dec 2019
- Primary completion
- Jul 2022
- Modality
- Covalent Small Molecules, Classical Binding Small Molecules, Nucleic Acid-Directed Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of hydroxytriptolide in human immunodeficiency virus infection (HIV), sponsored by Shanghai Pharmaceuticals Holding Co Ltd. Started Dec 2019; status: completed.
02
Drugs
hydroxytriptolide
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT04084444.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04084444.